Showing results (401-410 of 447) with videos related to
Sort By:
Pageof 45
Nature Cancer|February 5, 2022
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.Nature Cancer|December 24, 2021
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studyAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238Jeffrey Weber, Michele Del Vecchio, Mario Mandalá, et al.European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.The New England Journal of Medicine|March 9, 2012
Intratumor heterogeneity and branched evolution revealed by multiregion sequencingMarco Gerlinger, Andrew J Rowan, Stuart Horswell, et al.The Lancet. Oncology|March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialJeffrey S Weber, Sandra P D'Angelo, David Minor, et al.The Lancet. Oncology|September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.The New England Journal of Medicine|September 29, 2019
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaJames Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, et al.The New England Journal of Medicine|April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.Pageof 45